Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001104659-16-163804

Director bought 161,000 shares at $14.00 ($2,254,000)

  • Director acquired 6,508,699 shares (conversion)

From the SEC's structured data for this filing

Trades in this filing

Bolzon Bradley J PhD · Director

Table I: Non-derivative

18 lines
Date Transaction Shares Price Value Owned after D/I
2016-10-24 Conversion : show line 1 in the form +437,247 676,895 I
2016-10-24 Conversion : show line 2 in the form +3,100,477 3,777,372 I
2016-10-24 Conversion : show line 3 in the form +231,077 4,008,449 I
2016-10-24 Purchase : show line 4 in the form +95,596 $14.00 $1,338,344 4,104,045 I
2016-10-24 Conversion : show line 5 in the form +2,754 2,754 I
2016-10-24 Conversion : show line 6 in the form +19,524 22,278 I
2016-10-24 Conversion : show line 7 in the form +1,454 23,732 I
2016-10-24 Purchase : show line 8 in the form +602 $14.00 $8,428 24,334 I
Open-market purchases · 161,000 sh · avg $14.00 · $2,254,000

Table II: Derivative

15 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2016-10-18 Grant or award : show line 19 in the form Stock Option (Right to Buy) +30,000 $14.00 2026-10-18 30,000 60,000 I
2016-10-24 Conversion : show line 20 in the form Series A-1 Preferred Shares −437,247 437,247 0 I
2016-10-24 Conversion : show line 21 in the form Series A-1 Preferred Shares −2,754 2,754 0 I
2016-10-24 Conversion : show line 22 in the form Series A-2 Preferred Shares −3,100,477 3,100,477 0 I
2016-10-24 Conversion : show line 23 in the form Series A-2 Preferred Shares −19,524 19,524 0 I
2016-10-24 Conversion : show line 24 in the form Series A-3 Preferred Shares −2,210,417 2,210,417 0 I
2016-10-24 Conversion : show line 25 in the form Series A-3 Preferred Shares −66,490 66,490 0 I
2016-10-24 Conversion : show line 26 in the form Series A-3 Preferred Shares −168,224 168,224 0 I
Loading xslF345X03/a4.xml…